FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283696489> ?p ?o ?g. }

• W4283696489 abstract "Abstract Background Although a few meta-analyses were conducted to compare the risk of incident atrial fibrillation (AF) between sodium-glucose cotransporter-2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and other anti-hyperglycemic agents using indirect or direct comparison, the above analyses showed conflicting results with each other. We aimed to evaluate the risk of new-onset AF associated with the use of SGLT2i, GLP-1RA, and dipeptidyl peptidase-4 inhibitor (DPP4i) among a large longitudinal cohort of diabetic patients. Methods In this nationwide retrospective cohort study based on the Taiwan National Health Insurance Research Database, a total of 344,893, 44,370, and 393,100 consecutive patients with type 2 diabetes without preexisting AF receiving GLP-1RA, SGLT2i, and DPP4i, respectively, were enrolled from May 1, 2016, to December 31, 2019. We used 1:1 propensity score matching (PSM) to balance covariates across paired study groups. Patients were followed from the drug index date until the occurrence of AF, death, discontinuation of the index drug, or the end of the study period (December 31, 2020), whichever occurred first. Results After PSM, there were 245,442, 43,682, and 39,190 paired cohorts of SGLT2i-DPP4i, SGLT2i-GLP-1RA, and GLP-1RA-DPP4i, respectively. SGLT2i treatment was associated with lower risk of new-onset AF in participants with type 2 diabetes compared with either DPP4i [hazard ratio (HR):0.90; 95% confidential interval (CI) 0.84–0.96; P = 0.0028] or GLP-1RA [HR 0.74; 95% CI 0.63–0.88; P = 0.0007] treatment after PSM. There was no difference in the risk of incident AF between GLP-1RA and DPP4i users [HR 1.01; 95% CI 0.86–1.19; P = 0.8980]. The above findings persisted among several important subgroups. Dapagliflozin was specifically associated with a lower risk of new-onset AF compared with DPP4i ( P interaction = 0.02). Conclusions Compared with DPP4i, SGLT2i but not GLP-1RA was associated with a lower risk of incident AF in patients with type 2 diabetes." @default.
• W4283696489 created "2022-06-30" @default.
• W4283696489 creator A5002654282 @default.
• W4283696489 creator A5003158130 @default.
• W4283696489 creator A5025361204 @default.
• W4283696489 creator A5038405190 @default.
• W4283696489 creator A5049753044 @default.
• W4283696489 creator A5054836375 @default.
• W4283696489 creator A5062403345 @default.
• W4283696489 creator A5069412202 @default.
• W4283696489 creator A5072714961 @default.
• W4283696489 creator A5077291181 @default.
• W4283696489 date "2022-06-28" @default.
• W4283696489 modified "2023-09-25" @default.
• W4283696489 title "The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study" @default.
• W4283696489 cites W2019200806 @default.
• W4283696489 cites W2036193982 @default.
• W4283696489 cites W2048470090 @default.
• W4283696489 cites W2067736115 @default.
• W4283696489 cites W2106960442 @default.
• W4283696489 cites W2126049444 @default.
• W4283696489 cites W2131490500 @default.
• W4283696489 cites W2144168223 @default.
• W4283696489 cites W2144559080 @default.
• W4283696489 cites W2146264128 @default.
• W4283696489 cites W2150052417 @default.
• W4283696489 cites W2154746519 @default.
• W4283696489 cites W2159969745 @default.
• W4283696489 cites W2264072095 @default.
• W4283696489 cites W2285069016 @default.
• W4283696489 cites W2305515418 @default.
• W4283696489 cites W2330875378 @default.
• W4283696489 cites W2425644022 @default.
• W4283696489 cites W2489491424 @default.
• W4283696489 cites W2519510391 @default.
• W4283696489 cites W2557072679 @default.
• W4283696489 cites W2626446274 @default.
• W4283696489 cites W2776744495 @default.
• W4283696489 cites W2789654094 @default.
• W4283696489 cites W2790252631 @default.
• W4283696489 cites W2888632254 @default.
• W4283696489 cites W2889208017 @default.
• W4283696489 cites W2894746763 @default.
• W4283696489 cites W2900413769 @default.
• W4283696489 cites W2912187960 @default.
• W4283696489 cites W2948612418 @default.
• W4283696489 cites W2969204371 @default.
• W4283696489 cites W2969786006 @default.
• W4283696489 cites W2976126564 @default.
• W4283696489 cites W2995527943 @default.
• W4283696489 cites W2999431040 @default.
• W4283696489 cites W3004108046 @default.
• W4283696489 cites W3004319546 @default.
• W4283696489 cites W3027398726 @default.
• W4283696489 cites W3080459529 @default.
• W4283696489 cites W3083985134 @default.
• W4283696489 cites W3088460171 @default.
• W4283696489 cites W3091750031 @default.
• W4283696489 cites W3095911463 @default.
• W4283696489 cites W3120494617 @default.
• W4283696489 cites W3128624487 @default.
• W4283696489 cites W3135034995 @default.
• W4283696489 cites W3136045622 @default.
• W4283696489 cites W3194012840 @default.
• W4283696489 cites W3206335847 @default.
• W4283696489 cites W3211468684 @default.
• W4283696489 cites W3214524979 @default.
• W4283696489 cites W4200064002 @default.
• W4283696489 cites W4200514620 @default.
• W4283696489 cites W4206445899 @default.
• W4283696489 cites W4220813442 @default.
• W4283696489 cites W4237510741 @default.
• W4283696489 doi "https://doi.org/10.1186/s12933-022-01549-x" @default.
• W4283696489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35765074" @default.
• W4283696489 hasPublicationYear "2022" @default.
• W4283696489 type Work @default.
• W4283696489 citedByCount "11" @default.
• W4283696489 countsByYear W42836964892022 @default.
• W4283696489 countsByYear W42836964892023 @default.
• W4283696489 crossrefType "journal-article" @default.
• W4283696489 hasAuthorship W4283696489A5002654282 @default.
• W4283696489 hasAuthorship W4283696489A5003158130 @default.
• W4283696489 hasAuthorship W4283696489A5025361204 @default.
• W4283696489 hasAuthorship W4283696489A5038405190 @default.
• W4283696489 hasAuthorship W4283696489A5049753044 @default.
• W4283696489 hasAuthorship W4283696489A5054836375 @default.
• W4283696489 hasAuthorship W4283696489A5062403345 @default.
• W4283696489 hasAuthorship W4283696489A5069412202 @default.
• W4283696489 hasAuthorship W4283696489A5072714961 @default.
• W4283696489 hasAuthorship W4283696489A5077291181 @default.
• W4283696489 hasBestOaLocation W42836964891 @default.
• W4283696489 hasConcept C126322002 @default.
• W4283696489 hasConcept C134018914 @default.
• W4283696489 hasConcept C156490143 @default.
• W4283696489 hasConcept C167135981 @default.
• W4283696489 hasConcept C17923572 @default.
• W4283696489 hasConcept C201903717 @default.
• W4283696489 hasConcept C207103383 @default.
• W4283696489 hasConcept C2777180221 @default.
• W4283696489 hasConcept C2778715236 @default.

• next